Tina Albertson, PhD

Dr. Tina Albertson is Chief Medical Officer and Head of Development of Lyell Immunopharma, a T-cell reprogramming company committed to curing solid tumors with cellular therapies.  Dr. Albertson has over a decade of leadership in the clinical drug development of biologics and cellular therapies, from first-in-human to registrational clinical trials.  Prior to Lyell, she was VP of Global Drug Development at Juno Therapeutics, a BMS company, where she led a global team in the development of lisocabtagene maraleucel, a CD19-directed CAR T-cell product, from the first patient treated to BLA submission.  Dr. Albertson is a Pediatric Oncologist by training and has her MD from Stanford University and her PhD in Cancer Biology from the University of Washington.